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Allergic asthma is a disease characterized by persistent allergen-driven airway inflammation, remodeling, and
airway hyperresponsiveness. CD4 T-cells, especially T-helper type 2 cells, play a critical role in orchestrating
the disease process through the release of the cytokines IL-4, IL-5, and IL-13. Allergen-specific
immunotherapy (SIT) is currently the only treatment with a long-term effect via modifying the natural
course of allergy by interfering with the underlying immunological mechanisms. However, although SIT is
effective in allergic rhinitis and insect venom allergy, in allergic asthma it seldom results in complete
alleviation of the symptoms. Improvement of SIT is needed to enhance its efficacy in asthmatic patients.
Herein, the immunoregulatory mechanisms underlying the beneficial effects of SIT are discussed with the
ultimate aim to improve its treatment efficacy.
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llergic asthma is recognized as a chronic inflam-
matory disease of the airways in which many
types of cells play a role, in particular mast cells,
eosinophils, B- and T-lymphocytes, and epithelial cells. It
is characterized by the production of allergen-specific
immunoglobulin (Ig)E antibodies, reversible airflow ob-
struction, airway hyperresponsiveness (AHR) to a wide
variety of specific or non-specific stimuli, chronic airway
inflammation, and airway remodeling (1). During the
past several decades, the prevalence of allergic asthma is
increasing dramatically (20% in every 10 years),
especially in children (2). Approximately, it affects
1015% of the population in most developed industrial
countries (2). Both genetic and environmental factors are
involved in allergic asthma. Genetic studies indicate that
multiple genes are linked to the onset of this disease (35).
However, the epidemic increase of asthma cannot be
explained by genetic changes in the population. Changes
in environment and lifestyle including isolation of houses
which increases numbers of house dust mite, and child-
hood immunizations have contributed to the increase
(69). In addition, epidemiological and clinical studies
have suggested a link between the relative decreased
exposure to bacteria or other pathogenic agents (such as
helminthes) during the first years of life, and the increase
in allergic asthma (1012); this is referred to as the
‘hygiene hypothesis.’
Pathogenesis of asthma
The concepts of the pathogenesis of allergic asthma are
illustrated in Fig. 1. The development of allergic asthma
requires sensitization to an environmental allergen, which
can occurs years before the onset of clinical symptoms
(6, 13). For allergic sensitization allergens are taken up
and processed by professional antigen-presenting cells
(APCs), such as dendritic cells (DCs) and presented to
allergen-specific T-cells that subsequently differentiate
into T-helper (Th) 2-type cells. Activation of Th2 cells
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leads to the production of inflammatory cytokines, such
as interleukin 4 (IL-4) and IL-13, thereby stimulating
allergen-specific B-cells to proliferate and switch to
production of IgE (14, 15). Then IgE binds to high-
affinity IgE receptor FcoRI on mast cells. Upon re-
exposure, the allergen will bind to allergen-specific IgE on
mast cells thereby cross-linking the IgEFcoRI complexes
which subsequently cause the release of preformed
mediators like histamine and several other inflammatory
mediators (16, 17). These mast cell-derived mediators
cause the early asthmatic reaction which is characterized
by airway smooth muscle constriction, extensive vascular
leakage, mucus hypersecretion, enhanced airway respon-
siveness, and recruitment of inflammatory cells (1719).
In approximately 50% of the asthmatic patients this
early phase reaction is followed by the late phase
reaction. This phase is characterized by significant
involvement of infiltrated inflammatory cells, such as
eosinophils, T lymphocytes and macrophages, and re-
sident epithelial, endothelial and smooth muscle cells in
promoting the chronic symptoms of airway inflamma-
tion. In addition, these cells may also be an important
source of inflammatory mediators like chemokines,
cytokines, and leukotrienes in asthma.
Asthma: a CD4 T-helper type 2 (Th2)-mediated
disease
CD4 T-cells play a crucial role in controlling inflam-
mation in allergic asthma. They are the predominant
lymphocyte population that infiltrates the airways in
asthmatics and are activated in these sites, expressing the
surface activation markers class II histocompatibility
antigen [HLA-DR], CD25 (IL-2R), and very late activa-
tion antigen-1 (VLA-1) (20, 21). In addition to CD4
T-cells, CD8 T-cells, and g/d T-cells have been identified
in the airways of allergic asthmatics (21). About 60% of
the CD4 T-cells in the airway of persons with asthma
are invariant natural killer T (iNKT) cells (2225).
However, there is still controversy whether iNKT-cells
can induce allergic asthma in the absence of CD4
T-cells (2628).
Human and murine CD4 T-cells are divided into two
broad functional subsets according to their profiles of
cytokine secretion (29, 30). The conditions under which
CD4 Th cells become activated during an immune
response determine the development toward the Th1- or
the Th2-phenotype (31). CD4 Th1-type cells secrete
predominantly IL-2 and interferon gamma (IFN-g) and
are particularly implicated in cell-mediated immune
responses against invading intracellular pathogens, such
as viruses (32, 33). CD4 Th2-type cells produce a
different panel of cytokines including IL-4, IL-13, and
IL-5 (34). IL-4 promotes the development of Th2 cells
and together with other cytokines, promotes the growth
of mast cells, basophils, and eosinophils (35, 36).
Furthermore, IL-4 and IL-13 are required for the
induction of proliferation and isotype switching to IgE
by B-cells that recognize the allergen (14, 37). IL-5
secretion by Th2 cells is critical for eosinophil differentia-
tion and maturation (38, 39).
Fig. 1. Schematic representation of the pathophysiology of allergic asthma. In genetically predisposed individuals, primary
exposure to an allergen leads to activation of Th2 lymphocytes and stimulation of IgE synthesis. Later on, exposure causes
immediate release of the biologically active mediators (histamine, leukotrienes) via mast cell degranulation and further
activation of Th2 cells with resulting eosinophil inflammation and AHR.
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Over the years it became clear that the allergen-
induced airway inflammation is orchestrated by activated
Th2 cells. Th2-type lymphocytes play a critical role in the
initiation, progression, and persistence of allergic asthma.
Initially, a disturbed balance between Th1- and Th2-
mediated immune responses has been postulated to
underlie aberrant Th2 reactions to ‘innocuous’ environ-
mental antigens. Indeed, allergen-specific T-cell clones
isolated from the blood of allergic individuals express a
Th2 cytokine profile secreting IL-4, IL-5, and minimal
IFN-g and IL-2, whereas those clones from non-atopic
individuals displayed a Th1 profile (40). Furthermore,
allergic asthma is associated with the expression of IL-3,
IL-4, and IL-5 in bronchoalveolar cells, strongly support-
ing Th2 activation (41). Moreover, it has been shown that
when antigen-specific Th2 cells activated with inhaled
antigen, Th2 cells-induced airway eosinophilia, mucus
hypersecretion, and AHR after short-exposure to anti-
gen, while Th1 cells resulted in a neutrophil-predominant
inflammatory response without mucus production or
AHR (42, 43), indicating that Th1 cells alone do not
produce any of the characteristic features of asthma. In
human studies, CD4 T-cells producing IL-4, IL-5, and
IL-13 have been identified in bronchoalveolar lavage fluid
and airway biopsies from asthmatics patients. These
cytokines are secreted in the airways of patients with
mild or asymptomatic disease (41). Furthermore, it has
been shown that CD4 Th2 lymphocytes are increased in
the airways of asthmatic patients after antigen challenge
(21, 44, 45).
Allergen-specific immunotherapy (SIT)
Current pharmacologic therapies for allergic asthma,
such as bronchodilators and inhaled corticosteroids, are
effective in reducing and preventing symptom develop-
ment, but do not reverse the progression of or cure this
disease. SIT is unique in that it not only reduces
symptoms, but also induces long-lasting disease remis-
sion. SIT has been shown to improve allergic dysfunction
and to re-direct the immune system away from the
allergic response.
SIT was first introduced at St. Mary’s Hospital
London, at the end of the nineteenth century and many
of the basic principles described remain valid today. In
1911, Noon carried out the first study of active immu-
nization to prevent allergy against grass pollen using s.c.
injection of a distilled water extract of the pollen of
timothy grass, Phleum pretense (46). In 1918, it was
generally accepted that hay fever, asthma, and anaphy-
laxis were the result from antibodies produced after
exposure to sensitizing antigen (47).
By 1961, a new technique was developed to allow in
vitro measurements of histamine release from cells in
whole blood in the presence of specific allergen before
and after treatment with ragweed extract (48). The
findings demonstrated that after SIT, histamine release
was completely abolished in a few patients and was
reduced in others. Five years later, a double-blind study
performed by Lichtenstein and Osler (49) demonstrated
that the treatment with crude ragweed extract or the
major allergen of ragweed ‘Amb a 1’ resulted in reduction
of cellular sensitivity in some patients. Treated patients
showed little correlation between cellular sensitivity and
symptom scores. This finding was accompanied with a
rise in blocking antibodies. After these results, the term
immunotherapy has been used to describe the process
because it greatly deals with complex immunologic
changes.
Specific immunotherapy (SIT) for allergic
asthma
SIT for the management of allergic asthma continues to
be a matter for discussion (5053). Abramson and
colleagues (51, 54, 55) performed a meta-analysis of all
trials published over the past 50 years of the twentieth
century, examining the impact of SIT in patients with
allergic asthma. Overall, SIT was efficacious of decreas-
ing asthma medication use, reducing bronchial hyperre-
sponsiveness, and improving asthma symptom scores.
While there was no consistent effect on lung function,
SIT significantly reduced the airways response to inhala-
tion of specific allergen, with some reduction in non-
specific AHR as well.
Mechanisms involved in specific
immunotherapy (SIT)
The potential mechanisms that have been proposed to
explain the beneficial effects of SITare illustrated in Fig. 2.
To explain the immunological mechanisms underlying
the clinical improvement, intensive research has concen-
trated upon the specific antibody response in serum
with respect to class and subclass distribution (56).
Studies showed that the allergen-specific IgE levels rise
temporarily during initial phase of SIT, but fall back to
pre-treatment levels during maintenance therapy (57).
Subsequently, it was demonstrated that SIT also induces
allergen-specific IgG (mostly IgG1 and IgG4) and in few
reported cases IgA levels (5860). These findings led to
the hypotheses that these IgG antibodies contribute to
the immunosuppressive effects of SIT by blocking IgE-
facilitated antigen presentation (61, 62) and that such
antibodies act as blocking antibodies by engaging low-
affinity Fc receptors for Ig (e.g. FcgRII) expressed by B
lymphocytes, basophils, and mast cells (60). In fact, a
substantial number of studies demonstrated increased
specific IgG4 levels together with clinical improvement
(63, 64). However, the role of IgG (and IgA) in SIT has
been questioned and it is not clear whether the significant
increase in IgG levels has a causal role in alleviating
symptoms or simply represents a bystander effect,
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occurring as a consequence of high allergen exposure. In
Fcg knockout mouse model of allergic asthma we found
that bronchoalveolar lavage (BAL) eosinophilia, Th2
cytokines, and serum ovalbumin (OVA)-specific IgE
levels were strongly suppressed by SIT, demonstrating
that IgG Fcg receptors have no major role in the
beneficial effects of SIT (unpublished data). Moreover,
results demonstrated that the suppression of allergen-
induced airway inflammation by SIT is not
B-cell dependent, ruling out a critical role for B-cells,
IgGs, and IgA in SIT in the mouse model of allergic
asthma.
Thus, in the context of allergic diseases, including
asthma, most research indicates that during SIT the
increase of IgG is an epiphenomenon, however, the role
of allergen-specific antibodies, as putative ‘blocking
factors(s),’ in SIT providing protection against allergic
disease appears unlikely.
T-cell tolerance
The generation of an effective immune response involves
antigen-specific T-cell expansion and differentiation of
effector function. T-cell activation requires at least two
distinct signals, including signaling via the antigen-
specific T-cell receptor and a co-stimulatory pathway
(31). Antigen stimulation of T-cells can lead either to a
positive immune response, characterized by proliferation,
differentiation, clonal expansion, and effector function,
or in the absence of an appropriate co-stimulatory signal
to a state of long-lasting unresponsiveness, termed anergy
(65). The most important co-stimulatory molecules
involved are CD28/CD152 (CTLA-4)CD80/CD86
(B7-1/-2) and CD40-CD154 (CD40 ligand) (6668).
Anergy induction can down-regulate both cellular and
humoral immune responses. The induction of T-cell non-
responsiveness or anergy as the mechanism of SIT is
supported by the observed diminution of allergen-specific
T-cell proliferation and cytokine production (69),
although in some instances IL-2 was able to restore these
functions (70). However, the usually increased IgG
production during SIT cannot be explained by the
induction of T-cell anergy (71, 72). Various methods for
anergy induction have been described. Stimulation of
T-cells with high doses of antigen in the absence of
appropriate co-stimulation or in the presence of IL-10
has been found to induce a profound form of anergy (73,
74). Under these conditions anergic T-cells showed
limited peripheral expansion and a significant amount
of death, with a residual subset of cells remaining that
were unresponsive to antigen restimulation both in vivo
and in vitro. It has been suggested that T-cells rendered
anergic in vivo and in vitro become regulatory T-cells that
can regulate other T-cell responses (75, 76).
Immune deviation toward T-helper type 1 (Th1)
responses
In the late 1980s, a favorable explanation was based on
the Th1/Th2 dichotomy in specific immune reactions
Fig. 2. Schematic representation of the potential immune deviation leading to the beneficial effects of SIT. Allergen SIT results
in both a shift in allergen-specific T-cells from Th2 to Th0/Th1 responses and the generation of IL-10 and TGF-b producing T
regulatory (Treg) cells. Allergen-specific Th1 immune responses protect against the development of allergic disorders by
inducing the production of IFN-g, which inhibits the development of Th2 cells. The regulatory cytokines IL-10 and TGF-b
induce switching of B cell responses in favor of IgG4 antibodies and IgA antibodies, respectively, and suppress IgE production.
IL-10 and TGF-b directly or indirectly suppress effector cells of allergic inflammation such as mast cells and eosinophils thereby
preventing release of mediators and late-phase inflammation. Sold gray arrows represent immune response pathway to natural
exposure; dotted arrows represent immune response pathway to IT; blocked lines represent inhibition.
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(29). Mechanistic studies demonstrated that SIT alters
the balance of cytokines released from Th-lymphocytes
with a shift from Th2-cells in association with allergic
inflammation toward Th1-cells that release IFN-g, which
inhibits Th2-cells (7779). Early studies showed that
allergen-specific T-cell clones shift from IL-4 to IFN-g
production after SIT (77, 80). However, the effects of SIT
on Th1 cytokine secretion are less consistent (81). In
humans, several clinical trials demonstrated a reduction
of the allergen-specific Th2 response, whereas the Th1
response remained undetectable (78, 82) and in a separate
study, SIT diminished both allergen-specific Th2 and Th1
responses (83). In experimental allergic asthma models
some studies have confirmed that the relation between
presence of Th1-associated cytokines and amelioration of
disease, but others have not found such effects (84). In
recent years, the concept of immune deviation toward
Th1 response by SIT lost favor with the alternative
observation on regulatory T-cells.
Adaptive regulatory T (Treg) cells are taking the center
stage as crucial immunoregulatory cells that may offer an
explanation for many of the observations that occur
during SIT that cannot be adequately explained by the
Th2 to Th1 shift (8587).
Regulatory T-cells
Several subsets of regulatory T-cells with distinct pheno-
types and mechanism of actions have been identified.
These include: (1) naturally occurring CD4CD25
Foxp3 T-cells (nTregs) that inhibit immune responses
through cell-to-cell contact, (2) CD4Foxp3 iTregs
induced in the periphery, in contrast to nTregs not
generated in the thymus; the capacity of these cells to
suppress the proliferation of naı̈ve T-cells requires cell
cell contact, and (3) cells induced in the periphery
following antigen exposure (aTreg cells). aTreg cells are
subdivided into type 1 regulatory T (Tr1) cells which
secrete high levels of IL-10 and low to moderate levels of
transforming growth factor (TGF)-b and type 3 regula-
tory T (Th3) cells which secrete TGF-b.
Natural CD4CD25Foxp3 T regulatory cells
The natural CD4CD25Foxp3 regulatory T (nTreg)
cells are generated in the thymus and represent 510% of
the CD4 T lymphocytes both in mice and humans.
These cells are thought to perform a specialized role in
controlling both the innate and the adaptive immune
response (88, 89). Depletion of nTreg cells leads to the
spontaneous development of various autoimmune dis-
eases (9096). Although the mechanism of immune
regulation mediated by nTreg cells is not well understood,
these cells can both directly suppress responding T-cells
and down-modulate APC function in vitro (97, 98). nTreg
cells may also convert CD4 Th cell into regulatory cells
expressing IL-10 and/or TGF-b in culture systems (99,
100). It has been shown that nTreg cells induce infectious
tolerance in vivo by catalyzing the formation of IL-10
producing regulatory T-cells (101).
Adaptive T regulatory cells
In recent years, it has been demonstrated that SIT is
associated with the induction of aTreg cells. The aTreg
cells are generated in the periphery from naı̈ve T-cells
after encountering antigens presented by tolerogenic
DCs. In studies of SIT for bee venom anaphylaxis,
Akdis et al. (85) were the first to provide evidence for a
role of IL-10 and Tr1 cells in the beneficial effects of
SIT. They observed that the therapy-induced increase in
secretion of IL-10 in T-cell cultures along with de-
creased allergen-driven proliferation and decreased pro-
duction of Th2 and Th1 cytokines. Moreover, in clinical
trials, SIT has been shown to increase the production of
IL-10 by APCs, including B cells, monocytes, and
macrophages (61, 87, 102). Findings were extended by
SIT studies with airborne allergens that showed in-
creases in IL-10 and TGF-b producing antigen-specific
Treg cells in the blood and airway tissue (61, 8587).
Induction of IL-10 producing Tr1 cells has been shown
to be associated with successful SIT (85, 86). Animal
studies confirmed the suppressive role of IL-10 during
allergic inflammatory diseases (84, 103106). In human
studies, the regulatory cytokine IL-10 has been shown to
increase the production of IgG4 while preventing IL-4-
mediated class switching to IgE (107). Furthermore, IL-
10 down-regulate IgE-dependent activation of basophils
and mast cells, and decrease survival and activation of
eosinophils (108). In addition, IL-10 (and TGF-b) might
act on APCs. IL-10 down-regulates Major Histocom-
patability Complex (MHC) class II expression on
monocytes and reduces their antigen presentation capa-
city (109). Moreover, IL-10 down-regulates the CD80
expression on DCs and macrophages (110, 111). IL-10
may therefore block the APC dependent CD28CD80
interaction and subsequent co-stimulatory signaling in
T-cells (112).
The other immunoregulatory cytokine associated with
regulatory T-cells is TGF-b. Studies have provided
evidence for increases in the amount of TGF-b-driven
allergen-specific IgA following SIT, indicating other
antibody classes than IgG might contribute to clinical
efficacy (87). Moreover, TGF-b has been shown to induce
the expression of IL-10 by T-cells (113). Literature data
suggest that early increase in IL-10 (85) and sustained
TGF-b production may be required for successful SIT to
induce stable tolerance to non-pathogenic environmental
antigens (114).
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Role of dendritic cells (DCs) in generation of adaptive
regulatory T (aTreg) cells
Although there is suggestive evidence that SIT achieves
beneficial effectiveness by the induction of aTreg cells, the
mechanism by which SIT induces aTreg cells is not
completely understood. Over the past decade, it has
become clear that DCs play a critical role in the
generation of all aTreg cell subsets (115) and regulation
of immune responses to a variety of antigens (116). The
ability of DCs to induce immunity or tolerance depends
on their maturation state. Tolerogenic DCs are semi-
mature cells with increased expression of MHC II and
CD86 but low levels of expression of CD40 and absence
of the pro-inflammatory cytokines IL-6 and TNF-a
(117). It has been shown that aTreg cells induced by
immature DCs are characterized by high levels of IL-10
cytokine secretion (118, 119). The nuclear factor-kB
(NF-kB) protein Re1B activity is critically required for
DCs maturation (120). Re1B-deficient bone marrow-
derived DCs (BMDCs) or BMDCs in which Re1B
activity is inhibited have the potential to induce anti-
gen-specific immune tolerance in vivo (121). Inhibition of
NF-kB signaling by various drugs (122124) induces DCs
to acquire tolerogenic properties that favor the induction
of Tr1-like cells in vitro and tolerance in mouse models of
transplantation and autoimmune diseases (125127).
Besides this, recent findings demonstrate that DCs
induce development of aTreg cells by several mechanisms
including high expression of the tryptophan-catabolizing
enzyme indoleamine 2,3-dioxygenase (IDO) (128, 129).
IDO expressing DCs inhibit T-cell proliferation in vitro
and promote tolerance in vivo (130, 131), including
maternal tolerance during pregnancy (132), control of
allograft rejection (133), and protection against autoim-
munity (134). A number of studies have also demonstrated
that IDO is implicated in tolerance induction by regula-
tory T-cells expressing cytotoxic T-lymphocyte antigen-4
(CTLA-4) (135, 136). Moreover, IDO may directly
mediate inhibition of T-cells proliferation by tryptophan
depletion or downstream tryptophan metabolites (137,
138). Recently, we showed that inhibition of IDO
throughout SIT abrogated the efficacy of SIT on the
reduction of BAL eosinophil numbers and AHR to
methacholine, but no changes in serum OVA-specific
IgE levels were observed (139). In addition, we demon-
strated that inhibition of IDO throughout the aerosol
challenge period did not interfere with tolerance induction
by SIT. These findings reveal that IDO plays a role only
during induction of tolerance by SIT and that activity of
IDO is irrelevant for the effects of SIT thereafter. More-
over, considering the conceptual possibilities that either
tryptophan depletion or downstream tryptophan meta-
bolites mediated-IDO immunoregulation we showed
that formation of tryptophan metabolites, rather than
tryptophan depletion, is the mechanism by which SIT
induces tolerance to the induction of airway manifesta-
tions of asthma.
Improvement of specific immunotherapy (SIT)
The goal of SIT is the transformation of an allergic
individual into one who can tolerate allergen exposure
by converting deleterious allergic immune response into
protective responses. Despite the impressive efficacy of
allergen (injection) SIT for treatment of allergic rhinitis
and insect venom allergy, its efficacy in allergic asthma
remains controversial (51). Furthermore, it has been
reported that s.c. administration of allergens can induce
severe systemic reactions due to cross-linking of aller-
gen-specific IgE on mast cells (140, 141). Thus, for
development of a more effective and safe form of SIT,
more insight into the underlying immunological me-
chanisms of allergen IT is considered necessary to
improve efficacy, in particular in asthmatic patients.
There is growing evidence that the positive effects of
SIT are associated with aTreg cells (Tr1 and Th3) and
the immunosuppressive cytokines that they produce.
The mechanisms by which these cells are induced by
SIT are still not fully understood. Well-described path-
ways to induce aTreg cells are antigen presentation to
T-cell by immature DCs or the presence of IL-10 or
TGF-b in the local microenvironment. In this regard,
combination of SIT with administration of compounds
that inhibit DCs maturation, such as the biologically
active form of vitamin D3 (1a,25-dihydroxyvitamin D3)
or glucocorticoids, might be novel immunotherapeutic
strategies to improve SIT for better treatment of
allergic diseases, including allergic asthma. Interestingly,
in a mouse model of allergen immunotherapy, we
recently demonstrated that co-administration of 1a,25-
dihydroxyvitamin D3 effectively suppressed AHR to
methacholine and potentiated the reduction of serum
allergen-specific IgE levels and BAL eosinophilia in the
suboptimal SIT regime matched by a reduction in Th2
cytokines, IL-5, and IL-13 (142). We further observed
that in vitro antigen-induced productions of Th2-
cytokines are decreased in lung-draining lymph node
cells after this combination SIT. Moreover, data
demonstrates that the immunoregulatory cytokines IL-
10 and TGF-b are involved in tolerance to allergen-
induced airway manifestation of asthma since the
suppressive effects of combined SIT are completely
abrogated by blocking of the IL-10R and neutralizing
of TGF-b by using mAbs at the time of antigen
inhalation challenge.
Conclusion
Peripheral (naturally occurring and adaptive) T- cell
tolerance is the key immunological mechanism in
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healthy immune response to self- and non-infectious
non-self-antigen. Changes in the balance between aller-
gen-specific Treg and Th2, and/or Th1 cells are very
crucial in the development and also treatment of allergic
diseases. Understanding of the immunological mechan-
isms that lead to tolerance induction by SIT, Fig. 3, in
particular the role of regulatory T-cells in allergen-
specific peripheral tolerance may lead to more rational
and safer approaches that could result in prevention and
cure of allergic diseases, including asthma.
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